Telo Genomics Corp.

About Telo Genomics Corp.

TeloGenomics is focused on developing highly predictive and non-invasive prognostic and diagnostic applications using their proprietary 3D telomere technology, TeloView(r), to improve disease treatment by providing actionable information on disease aggressiveness and potential treatment responses.

Products & Services

TeloView(r):A proprietary technology that quantifies genomic instability by measuring the 3D structure and spatial organization of telomeres, aiding in assessing disease aggressiveness and treatment response.

Smoldering Multiple Myeloma (SMM):A diagnostic application focused on smoldering multiple myeloma.

MRD Solutions:Solutions for minimal residual disease monitoring.

Alzheimer's Disease:Applications targeting Alzheimer’s disease diagnostics.

Prostate Cancer:Diagnostic solutions for prostate cancer.

Specialties

Telomere Science Genomic Instability Analysis Cancer Diagnostics Neurodegenerative Disease Diagnostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 2000000 MR: - FA: $2,000,000 FAN: 2000000	D: 2023-05-19 FD: 2023-05-19	-

Private Placement Latest

2023-05-19

$2.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dr. Mai

Founder of Telo Genomics

S

Sabine Mai

Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, Professor in multiple disciplines, and Director of The Genomic Centre for Cancer Research and Diagnosis at the University of Manitoba

G

Guido Baechler

EXECUTIVE CHAIRMAN

D

Dr. Sabine Mai

Interim CEO, Director and Co-Founder

M

Mark Stene

Head of Laboratory Operations

C

Chris Ross

CFO

View 14 more team members with Pro

Unlock Full Team Directory

Recent News